PF-05212377

PF-05212377 (also known as SAM-760) is a potent and selective antagonist of the 5-hydroxytryptamine 6 (5-HT6) receptor, developed for the treatment of Alzheimer's disease. It is a small molecule that demonstrates good blood-brain barrier permeability and has shown central 5-HT6 receptor saturation in humans at clinically relevant doses. The drug was investigated primarily for its potential to improve cognition and neuropsychiatric symptoms in patients with mild-to-moderate Alzheimer's disease who were already receiving donepezil therapy. Clinical trials included randomized, placebo-controlled studies to assess safety, tolerability, pharmacokinetics, and efficacy on cognitive endpoints[1][4][6][7].